The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IACH Focus on Leukemia 2020 | The search for better post-MPN AML treatment: decitabine and ruxolitinib
Although post-myeloproliferative neoplasm acute myeloid leukemia (post-MPN AML) is relatively rare, patients with this condition represent a population with an urgent unmet medical need. Farhad Ravandi, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the difficulties finding treatments that are effective for post-MPN AML. With the traditional chemotherapy treatment, patients only survive a few months, especially patents with a history of myelofibrosis. Therefore, there was an effort to combine decitabine and ruxolitinib to hopefully find a more effective treatment. However, the results only indicated a small improvement over decitabine alone. This interview took place during the 2020 Annual Meeting of the International Academy for Clinical Hematology (IACH).
